CN110402088A - 用于改善肠道内环境的食品 - Google Patents
用于改善肠道内环境的食品 Download PDFInfo
- Publication number
- CN110402088A CN110402088A CN201880019869.7A CN201880019869A CN110402088A CN 110402088 A CN110402088 A CN 110402088A CN 201880019869 A CN201880019869 A CN 201880019869A CN 110402088 A CN110402088 A CN 110402088A
- Authority
- CN
- China
- Prior art keywords
- food
- amino acid
- indigestible polysaccharide
- salt
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013305 food Nutrition 0.000 title claims abstract description 81
- 230000000968 intestinal effect Effects 0.000 title claims abstract description 35
- 239000000203 mixture Substances 0.000 claims abstract description 74
- 150000004676 glycans Chemical class 0.000 claims abstract description 66
- 150000001413 amino acids Chemical class 0.000 claims abstract description 65
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 62
- 239000005017 polysaccharide Substances 0.000 claims abstract description 62
- 150000003839 salts Chemical class 0.000 claims abstract description 37
- 235000001014 amino acid Nutrition 0.000 claims description 64
- 229920001542 oligosaccharide Polymers 0.000 claims description 40
- 150000002482 oligosaccharides Chemical class 0.000 claims description 40
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 32
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 30
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 18
- 239000004472 Lysine Substances 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 16
- 235000018977 lysine Nutrition 0.000 claims description 15
- 239000008187 granular material Substances 0.000 claims description 14
- 235000013922 glutamic acid Nutrition 0.000 claims description 11
- 239000004220 glutamic acid Substances 0.000 claims description 11
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 10
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 8
- 239000007901 soft capsule Substances 0.000 claims description 8
- 235000014393 valine Nutrition 0.000 claims description 8
- 239000004474 valine Substances 0.000 claims description 8
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 7
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 7
- 235000004279 alanine Nutrition 0.000 claims description 7
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 7
- 235000004554 glutamine Nutrition 0.000 claims description 7
- 239000007902 hard capsule Substances 0.000 claims description 7
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 5
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 5
- 235000014304 histidine Nutrition 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 235000013930 proline Nutrition 0.000 claims description 5
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 229910021529 ammonia Inorganic materials 0.000 claims description 4
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 241000186000 Bifidobacterium Species 0.000 abstract description 37
- 230000035755 proliferation Effects 0.000 abstract description 16
- 230000001737 promoting effect Effects 0.000 abstract description 5
- 150000004804 polysaccharides Polymers 0.000 abstract description 3
- 229940024606 amino acid Drugs 0.000 description 58
- 238000012360 testing method Methods 0.000 description 25
- 235000013325 dietary fiber Nutrition 0.000 description 17
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 14
- 150000003271 galactooligosaccharides Chemical class 0.000 description 14
- -1 oligosaccharides Chemical class 0.000 description 13
- 229960002989 glutamic acid Drugs 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 238000003753 real-time PCR Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 241000252983 Caecum Species 0.000 description 7
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 7
- 210000004534 cecum Anatomy 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- 229960003767 alanine Drugs 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 229920001202 Inulin Polymers 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 229940029339 inulin Drugs 0.000 description 5
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 5
- 210000002429 large intestine Anatomy 0.000 description 5
- 238000006116 polymerization reaction Methods 0.000 description 5
- 210000000813 small intestine Anatomy 0.000 description 5
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 229960003646 lysine Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 235000019766 L-Lysine Nutrition 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000007931 coated granule Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 239000002702 enteric coating Substances 0.000 description 3
- 238000009505 enteric coating Methods 0.000 description 3
- 229940031098 ethanolamine Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 235000014705 isoleucine Nutrition 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 235000013406 prebiotics Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000002662 enteric coated tablet Substances 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 235000005772 leucine Nutrition 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 235000006109 methionine Nutrition 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229960005190 phenylalanine Drugs 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000004400 serine Nutrition 0.000 description 2
- 235000008521 threonine Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- FVVCFHXLWDDRHG-UPLOTWCNSA-N (2s,3r,4s,5r,6r)-2-[(2r,3s,4r,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 FVVCFHXLWDDRHG-UPLOTWCNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 229920001875 Ebonite Polymers 0.000 description 1
- 229920003139 Eudragit® L 100 Polymers 0.000 description 1
- 229920003141 Eudragit® S 100 Polymers 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000533293 Sesbania emerus Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- 229910000329 aluminium sulfate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 159000000009 barium salts Chemical class 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 150000003272 mannan oligosaccharides Chemical class 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 235000008729 phenylalanine Nutrition 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- GGHDAUPFEBTORZ-UHFFFAOYSA-N propane-1,1-diamine Chemical compound CCC(N)N GGHDAUPFEBTORZ-UHFFFAOYSA-N 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 229960004418 trolamine Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/60—Feeding-stuffs specially adapted for particular animals for weanlings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/25—Synthetic polymers, e.g. vinylic or acrylic polymers
- A23L33/26—Polyol polyesters, e.g. sucrose polyesters; Synthetic sugar polymers, e.g. polydextrose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Nutrition Science (AREA)
- Birds (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明旨在提供一种用于通过促进肠道内双歧杆菌的增殖来改善肠道内环境的食品。一种用于改善肠道内环境的食品,该食品是将(1)含有氨基酸或其盐的肠溶性组合物及(2)难消化性多糖类或含有难消化性多糖类的组合物组合而成。
Description
技术领域
本发明涉及一种用于通过促进肠道内双歧杆菌的增殖来改善肠道内环境的食品。
背景技术
促进肠道内双歧杆菌等有益菌的增殖并改善肠道内环境(肠道内细菌菌群的正常化)对于各种疾病的预防和健康的促进与维持是重要的。
专利文献1公开了含有益生元的甜味剂组合物并且描述了益生元包括粘多糖、寡糖、多糖、氨基酸、维生素、营养素前体、蛋白质和这些的组合。然而,该文献未显示证明上述益生元引起胃肠道中双歧杆菌增殖的试验例。
非专利文献1报道了双歧杆菌的氨基酸需要性。然而,该报告显示使用比肠道内更富含营养的培养基的纯培养菌株的试验结果,并且尚未研究诸如下消化道或寡营养且诸如肠道内细菌菌群的复杂体系。
已知多糖类如寡糖和水溶性膳食纤维(例如菊粉)难以在胃和小肠中消化与吸收,到达大肠成为诸如双歧杆菌等有益菌的饵料(例如非专利文献2、非专利文献3)。
文献清单
专利文献
专利文献1:日本专利特表2009-517032号公报
非专利文献
非专利文献1:“Bifidobacteria Research(双歧杆菌的研究)” 光冈知足,Center forAcademic Publications Japan (日本学术出版中心),1998年,P70
非专利文献2:GIBSON等人,GASTROENTEROLOGY, Vol. 108, No. 4,第 975-982页,1995
非专利文献3:Kolida等人,Br J Nutr. 2002年5月;87增补版2: S193-197。
发明内容
本发明所要解决的技术问题
本发明旨在提供一种用于通过促进肠道内双歧杆菌的增殖来改善肠道内环境的食品。
解决技术问题用的手段
本发明人已经进行了深入研究以试图解决上述问题,并且从下述试验例1-1、1-2和2(使用人粪便悬浮液的培养试验)的结果、进而从试验例3(对猪的施用试验)的结果发现:通过供给寡糖(难消化性多糖类)和氨基酸的组合作为活性成分,与单独使用每一种时相比,获得显著优异的双歧杆菌的增殖促进作用。
此外,氨基酸通常在空肠和回肠前段被吸收,并且认为它们不容易到达双歧杆菌生存的下消化道。然而,本发明人已经发现:通过形成氨基酸的肠溶性组合物,可以在下消化道中同时存在寡糖(难消化性多糖类)和氨基酸。
本发明人已经基于上述发现进行了进一步的研究并完成了本发明。
即,本发明提供以下内容,
[1] 一种用于改善肠道内环境的食品,该食品是将下述的(1)和(2)组合而成:
(1)含有氨基酸或其盐的肠溶性组合物、
(2)难消化性多糖类或含有难消化性多糖类的组合物;
[2] 上述[1]所述的食品,其中,难消化性多糖类或含有难消化性多糖类的组合物为寡糖或含有寡糖的组合物;
[3] 上述[1]或[2]所述的食品,其中,氨基酸为选自丙氨酸、谷氨酰胺、谷氨酸、异亮氨酸、组氨酸、赖氨酸、脯氨酸及缬氨酸中的一种或两种以上的组合;
[3-1] 上述[1]或[2]所述的食品,其中,氨基酸为选自丙氨酸、谷氨酰胺、谷氨酸、异亮氨酸、赖氨酸及缬氨酸中的一种或两种以上的组合;
[4] 上述[1]或[2]所述的食品,其中,氨基酸为谷氨酸、赖氨酸、或者谷氨酸与赖氨酸的组合;
[5] 上述[1]至[4]中任一项所述的食品,其中,肠溶性组合物为颗粒剂、粒化物(granulated substance)、片剂、硬胶囊或软胶囊;
[6] 上述[2]至[5]中任一项所述的食品,其中,含有寡糖的组合物为含有寡糖的饮料;
[7] 一种商业包装,其包含:
将(1)含有氨基酸或其盐的肠溶性组合物及(2)难消化性多糖类或含有难消化性多糖类的组合物组合而成的食品、以及
记载了与用于改善肠道内环境的用途相关的说明的书面材料;
[8] 附有其用于改善肠道内环境的指示(indication)的食品,该食品是将下述的(1)和(2)组合而成:
(1)含有氨基酸或其盐的肠溶性组合物、
(2)难消化性多糖类或含有难消化性多糖类的组合物;
[9] 用于增强肠道内环境改善作用的食品,该食品是将下述的(1)和(2)组合而成:
(1)含有氨基酸或其盐的肠溶性组合物、
(2)难消化性多糖类或含有难消化性多糖类的组合物;
[10] 用于增强难消化性多糖类或含有难消化性多糖类的组合物的肠道内环境改善作用的食品,该食品为含有氨基酸或其盐的肠溶性组合物;
[11] 一种食品,该食品用于改善肠道内环境,并且该食品是将下述的(1)和(2)组合而成:
(1)含有氨基酸或其盐的肠溶性组合物、
(2)难消化性多糖类或含有难消化性多糖类的组合物;
[12] 一种改善人肠道内环境的方法,其特征在于,由人摄取有效量的将下述的(1)和(2)组合而成的食品:
(1)含有氨基酸或其盐的肠溶性组合物、
(2)难消化性多糖类或含有难消化性多糖类的组合物;
[13] (1)含有氨基酸或其盐的肠溶性组合物及(2)难消化性多糖类或含有难消化性多糖类的组合物在制造用于改善肠道内环境的食品中的用途。
本发明还提供以下内容,
[14] 一种用于改善肠道内环境的食品,该食品是将下述的(1)和(2)组合而成:
(1)含有氨基酸的肠溶性组合物、
(2)寡糖或含有寡糖的组合物;
[15] 上述[14]所述的食品,其中,氨基酸为选自丙氨酸、谷氨酰胺、谷氨酸、异亮氨酸、赖氨酸及缬氨酸中的一种或两种以上的组合;
[16] 上述[14]所述的食品,其中,氨基酸为谷氨酸、赖氨酸、或者谷氨酸与赖氨酸的组合;
[17] 上述[14]至[16]中任一项所述的食品,其中,肠溶性组合物为颗粒剂、片剂、硬胶囊或软胶囊;
[18] 上述[14]至[17]中任一项所述的食品,其中,含有寡糖的组合物为含有寡糖的饮料;
[19] 一种商业包装,其包含:
将(1)含有氨基酸的肠溶性组合物及(2)寡糖或含有寡糖的组合物组合而成的食品、以及
记载了与用于改善肠道内环境的用途相关的说明的书面材料;
[20] 附有其用于改善肠道内环境的指示的食品,该食品是将下述的(1)和(2)组合而成:
(1)含有氨基酸的肠溶性组合物、
(2)寡糖或含有寡糖的组合物;
[21] 用于增强肠道内环境改善作用的食品,该食品是将下述的(1)和(2)组合而成:
(1)含有氨基酸的肠溶性组合物、
(2)寡糖或含有寡糖的组合物;
[22] 用于增强寡糖或含有寡糖的组合物的肠道内环境改善作用的食品,该食品为含有氨基酸的肠溶性组合物。
发明效果
根据本发明,通过供给难消化性多糖类(例如寡糖、水溶性膳食纤维)和氨基酸或其盐的组合,可提供与单独使用每一种时相比具有显著优异的双歧杆菌的增殖促进作用且具有改善肠道内环境的功能的食品。
根据本发明,通过供给氨基酸或其盐(作为肠溶性组合物)和难消化性多糖类(例如寡糖、水溶性膳食纤维)的组合,从而难消化性多糖类(例如寡糖、水溶性膳食纤维)和氨基酸或其盐可同时存在于双歧杆菌生存的下消化道,并可促进肠道内双歧杆菌的增殖。
附图说明
图1-1显示试验例1-1的结果;
图1-2显示试验例1-2的结果;
图2显示试验例2的结果;
图3显示试验例3中盲肠内双歧杆菌的相对量的结果;
图4显示试验例3中盲肠内赖氨酸浓度的结果。
具体实施方式
下面详细描述本发明。
本发明的用于改善肠道内环境的食品是将(1)含有氨基酸或其盐的肠溶性组合物及(2)难消化性多糖类或含有难消化性多糖类的组合物组合组成。
本发明的食品是将(1)和(2)组合使用的、(1)和(2)的并用食品。
在本发明的食品中,(1)和(2)可以同时配制(制剂化)并包含于同一制剂(食品)中,或者(1)和(2)可以分别配制并通过相同路径或不同路径同时或在不同时间(间隔时间差)摄取。即本发明的食品包括:在单个制剂中含有(1)和(2)的食品,以及将(1)和(2)分别配制并组合使用的食品。
在本说明书中,食品是一个广泛涵盖可口服摄取的食品(不包括药品)的概念,并且不仅包括所谓的“食品”,还包括饮料、健康辅助食品、保健功能食品(例如特定保健用食品、具有功能性声称的食品)、补充剂等。
在本说明书中,“肠道内环境改善”是指相对增加在下消化道中存在的双歧杆菌。相对增加意味着促进双歧杆菌在肠道内细菌菌群中的优势。通过使用定量PCR等测量粪便中双歧杆菌的量,可以确认双歧杆菌在肠道内细菌菌群中的优势。
在本说明书中,“下消化道”是指回肠、盲肠、结肠和直肠。
(1)含有氨基酸或其盐的肠溶性组合物
本发明中的氨基酸的实例包括丙氨酸、精氨酸、天冬酰胺、半胱氨酸、谷氨酰胺、谷氨酸、甘氨酸、组氨酸、异亮氨酸、亮氨酸、赖氨酸、蛋氨酸、苯丙氨酸、脯氨酸、丝氨酸、苏氨酸和缬氨酸,优选丙氨酸、谷氨酰胺、谷氨酸、异亮氨酸、组氨酸、赖氨酸、脯氨酸和缬氨酸。这些氨基酸优选呈L形式。氨基酸可使用一种或将两种以上组合使用。
作为本发明中的氨基酸,优选L-丙氨酸、L-谷氨酰胺、L-谷氨酸、L-异亮氨酸、L-组氨酸、L-赖氨酸、L-脯氨酸、L-缬氨酸或这些的组合(例如L-谷氨酸与L-赖氨酸的组合),并且更优选L-谷氨酸、L-赖氨酸、或L-谷氨酸与L-赖氨酸的组合。
本发明中的氨基酸可呈盐的形式。实例包括作为药物或食品可接受的盐。例如可提及:碱金属盐如钠盐、钾盐等;碱土金属盐,如钙盐、镁盐、钡盐等;铝盐;与有机碱如乙二胺、丙二胺、乙醇胺、单烷基乙醇胺、二烷基乙醇胺、二乙醇胺、三乙醇胺等的盐;与无机酸如盐酸、氢溴酸、硝酸、硫酸、磷酸等的盐;以及与有机酸如甲酸、乙酸、三氟乙酸、邻苯二甲酸、富马酸、草酸、酒石酸、马来酸、柠檬酸、琥珀酸、苹果酸、甲磺酸、苯磺酸、对甲苯磺酸等的盐,优选钠盐、钾盐或盐酸盐。
在本发明中,肠溶性组合物是在pH低的胃或小肠上段中不崩解但在pH高的小肠下段或大肠中崩解且释放氨基酸或其盐的组合物。
本发明中的肠溶性组合物优选在pH4或更高(更优选pH4~pH9,进一步优选pH5~pH9)崩解。
崩解性例如可以根据第17版日本药典中崩解试验方法的肠溶制剂的规定来测定。
本发明中的肠溶性组合物的实例包括颗粒剂(包括细粒剂)、粒化物、片剂、硬胶囊和软胶囊。
本发明中的肠溶性组合物可通过食品制剂或药物制剂领域中已知的方法制备。
例如可提及:包括将氨基酸或其盐与载体(例如赋形剂、粘合剂、崩解剂、润滑剂、保护剂)一起混合、造粒和/或压片以得到颗粒剂或片剂,对其实施肠溶包衣以得到肠溶颗粒剂或肠溶片剂的方法;包括将含有氨基酸或其盐的颗粒剂或片剂填充至实施了肠溶包衣的硬胶囊中以得到肠溶胶囊的方法;以及包括将氨基酸或其盐在载体(例如油成分)中的悬浮液封入由肠溶基材形成的软胶囊中以得到肠溶胶囊的方法。此外,可将上述肠溶颗粒剂封入胶囊(例如纤维素胶囊)中以得到胶囊。此外,可通过将油和脂肪(保护剂)与氨基酸或其盐的熔融混合物冷却固化以得到肠溶粒化物。此外,亦可使用市售品。
肠溶包衣基材的实例包括:纤维素类高分子,如邻苯二甲酸羟丙甲纤维素酯、醋酸羟丙甲纤维素琥珀酸酯、羧甲基乙基纤维素、邻苯二甲酸乙酸纤维素等;丙烯酸类高分子,如甲基丙烯酸共聚物L、甲基丙烯酸共聚物LD、甲基丙烯酸共聚物S等;以及天然存在的物质,如虫胶等。在包衣过程中也可以使用包衣添加剂(例如增塑剂)。
以制剂技术领域中常规使用的量使用载体、包衣基材和包衣添加剂。
(2)难消化性多糖类或含有难消化性多糖类的组合物
在本说明书中,难消化性多糖类是难以在胃和小肠中消化或吸收,到达大肠成为双歧杆菌的饵料(被双歧杆菌利用)的多糖类。
在本发明中,难消化性多糖类的聚合度不低于2或不低于3。在本发明中,难消化性多糖类的聚合度的上限没有特别限定,例如不超过100,优选不超过60,更优选不超过10,进一步优选不超过6,进一步更优选不超过5。
在本发明中,难消化性多糖类的聚合度优选为2-100,更优选为2-60, 进一步优选为2-10,进一步更优选为2-6。
在本发明中,难消化性多糖类的实例包括寡糖、水溶性膳食纤维等。
在本发明中,作为(2),可使用难消化性多糖类(例如寡糖、水溶性膳食纤维)本身、或可使用含有难消化性多糖类(例如寡糖、水溶性膳食纤维)的组合物。
在本说明书中,寡糖具有结合到其上的2至10个单糖。
本发明中的寡糖的实例包括:咖啡豆甘露低聚糖、低聚乳果糖、低聚半乳糖、低聚果糖、大豆寡糖、低聚木糖和低聚异麦芽糖,并且优选低聚果糖或低聚半乳糖。寡糖可使用一种或将两种以上组合使用。
寡糖可通过已知方法制备,亦可使用市售品。
低聚果糖的实例包括聚合度为3-5的低聚果糖,其中1-3个果糖与蔗糖结合。具体地可提及例如FOS:和光纯药工业公司、#064-02385。
低聚半乳糖的实例包括聚合度为2-6的低聚半乳糖,其中半乳糖与乳糖结合。具体地可提及例如GOS:和光纯药工业公司、#076-05945。
在本发明中,水溶性膳食纤维是难以在胃或小肠中消化或吸收,并且到达大肠被肠道内细菌分解并被双歧杆菌利用(成为双歧杆菌的饵料)的膳食纤维。
在本发明中,水溶性膳食纤维的实例包括菊粉。
水溶性膳食纤维(例如菊粉)可通过已知方法制备,亦可使用市售品。
菊粉通常具有这样的结构,其中2-60 个果糖分子通过β(2-1)键聚合并且在末端结合有葡萄糖分子。
菊粉在大肠中被肠道内细菌分解(部分水解)成低聚果糖。因此,在消化道(胃肠道)中预期有与在下述试验例1-1、1-2中确认的低聚果糖的效果类似的效果。
本发明的含有难消化性多糖类(例如寡糖、水溶性膳食纤维)的组合物的形式没有特别问题,并且可以是例如散剂、颗粒剂(包括细粒剂)、片剂、硬胶囊、软胶囊、液体制剂(例如溶液、悬浮液、乳液)、饮料、果冻、布丁、酸奶、糖果、口香糖等。这些可通过已知方法制备。例如,可将难消化性多糖类(例如寡糖、水溶性膳食纤维)与载体(例如赋形剂、粘合剂、崩解剂、润滑剂、溶剂)混合,并通过食品制剂或药物制剂领域中的已知方法制备散剂、颗粒剂、片剂、胶囊、液体制剂等。此外,它们也可通过向食品和饮料(例如水、软饮料)中添加和混合难消化性多糖类(例如寡糖、水溶性膳食纤维)来制备。亦可使用市售品(例如明治FoodMateria公司制造的低聚果糖“Meioligo P 颗粒”)。
如上所述,本发明的食品包括:在单个制剂中含有上述(1)和(2)的食品,以及将上述(1)和(2)分别配制并组合使用的食品。
作为将(1)和(2)分别配制并组合使用的食品,可提及例如:将“含有氨基酸或其盐的肠溶颗粒剂、肠溶粒化物、肠溶片剂、肠溶硬胶囊或肠溶软胶囊形式的(1)”和“含有难消化性多糖类(例如寡糖、水溶性膳食纤维)的饮料形式的(2)”组合使用的食品。
在本发明中,可同时或在不同时间通过相同路径或不同路径摄取(1)和(2)。具体地例如,含有氨基酸或其盐的肠溶胶囊(例如硬胶囊、软胶囊)、肠溶颗粒剂、肠溶粒化物等可与含有难消化性多糖类(例如寡糖、水溶性膳食纤维)的饮料一起摄取。
本发明的用于改善肠道内环境的食品中氨基酸或其盐的成人(体重60 kg)每日摄取量(基于氨基酸)通常为0.1 - 50 g,优选为0.2 - 20 g,更优选为0.5 - 10 g。
本发明的用于改善肠道内环境的食品中难消化性多糖类(例如寡糖、水溶性膳食纤维)的成人(体重60 kg)每日摄取量通常为0.1 - 50 g,优选为0.2 - 20 g,更优选为0.5- 10 g。
本发明的食品可以安全地被人和除人以外的动物(例如哺乳动物和鸟类,如家畜、家禽、实验动物等)摄取。作为除人以外的动物的摄取形式,可以添加到饲料中。
在本发明的其他实施方式中,可提及“一种商业包装,其包含:将(1)含有氨基酸或其盐的肠溶性组合物及(2)难消化性多糖类或含有难消化性多糖类的组合物组合而成的食品、以及记载了与用于改善肠道内环境的用途相关的说明的书面材料”、“附有其用于改善肠道内环境的指示的食品,该食品是将(1)含有氨基酸或其盐的肠溶性组合物及(2)难消化性多糖类或含有难消化性多糖类的组合物组合而成”、“用于增强肠道内环境改善作用的食品,该食品是将(1)含有氨基酸或其盐的肠溶性组合物及(2)难消化性多糖类或含有难消化性多糖类的组合物组合而成”、以及“用于增强难消化性多糖类或含有难消化性多糖类的组合物的肠道内环境改善作用的食品,该食品为含有氨基酸或其盐的肠溶性组合物”。“含有氨基酸或其盐的肠溶性组合物”、“难消化性多糖类或含有难消化性多糖类的组合物”、“肠道内环境改善”、“氨基酸或其盐的摄取量”和“难消化性多糖类的摄取量”与针对上述用于改善肠道内环境的食品所说明的示例和定义相同。
实施例
以下基于试验例、实施例、比较例和参考例更详细地说明本发明,但本发明不受这些例子的限制。
缩写含义如下:
Ala: L-丙氨酸
Arg: L-精氨酸
Asn: L-天冬酰胺
Cys: L-半胱氨酸
Gln: L-谷氨酰胺
Glu: L-谷氨酸
Gly: 甘氨酸
His: L-组氨酸
Ile: L-异亮氨酸
Leu: L-亮氨酸
Lys: L-赖氨酸
Met: L-蛋氨酸
Phe: L-苯丙氨酸
Pro: L-脯氨酸
Ser: L-丝氨酸
Thr: L-苏氨酸
Val: L-缬氨酸
FOS: 低聚果糖
GOS: 低聚半乳糖
PBS: 磷酸缓冲盐水。
[试验例1-1] 向人粪便悬浮液添加氨基酸和低聚果糖的试验
制备用于表1-1中所示的实施例和比较例的PBS溶液,并作为粪便培养用的培养基。使用单独的PBS作为对照。使用和光纯药工业公司制造的低聚果糖(FOS) (#064-02385)。
然后,将各10ml分配到玻璃小瓶中,并通过高压釜对玻璃小瓶进行灭菌,使其厌氧,并用丁基橡胶塞密封。通过从20-40岁的健康个体3人(男性1人和女性2人)收集约10g粪便并将其悬浮于80ml厌氧PBS中来制备粪便悬浮液。将该粪便悬浮液加入到每个小瓶中0.5ml,置于37℃的培养箱中,并且以每天一次颠倒混合的方式厌氧培养4天。完成培养后,通过离心分离(8,000×g,5分钟)从全部量的培养基中获得肠道内细菌沉淀(bacterialpellet)。使用ISOFECAL for BeadsBeat(日本基因(NIPPON GENE)公司制造)从该沉淀中萃取DNA,并且使用GeneAce SYBR qPCR Mix α (日本基因公司制造)进行定量PCR。定量PCR在以下条件下进行:95℃下10分钟后,将95℃下30秒和60℃下60秒实施45个循环。用于检测双歧杆菌的定量PCR所用的引物如下:
g-Bifid-F:5’-CTCCTGGAAACGGGTGG-3’ (SEQ ID NO: 1)
g-Bifid-R:5’-GGTGTTCTTCCCGATATCTACA-3’ (SEQ ID NO: 2)。
[表1-1]
。
使用通过定量PCR获得的结果,计算将对照设为1时的相对量,并将其结果用Z-score(Z得分)标准化。
结果示于图1-1中。数据以Z-score的平均值±标准误差表示(n=3)。其结果,当单独添加任何氨基酸时,未观察到双歧杆菌的增殖。然而,当Ala、Gln、Glu、Ile、Lys和Val分别与0.5%FOS一起添加时,观察到比单独用FOS更显著的双歧杆菌的增殖。此外,当Glu和Lys混合并与0.5%FOS一起添加时,类似地观察到比单独用FOS更显著的双歧杆菌的增殖。
因此,在本发明中,通过组合氨基酸和寡糖,在双歧杆菌的增殖方面观察到超过加和效应的协同效应。
[试验例 1-2] 向人粪便悬浮液中添加氨基酸和低聚果糖的试验
制备表1-2中所示的实施例和比较例的PBS溶液,并作为粪便培养用的培养基。使用单独的PBS作为对照。根据与试验例1-1中的方法类似的方法,进行粪便培养和双歧杆菌的检测。
[表1-2]
。
使用通过定量PCR获得的结果,计算将对照设为1时的相对量,并将其结果用Z-score(Z得分)标准化。
结果示于图1-2中。数据以Z-score的平均值±标准误差表示(n=3)。其结果,当单独添加任何氨基酸时,未观察到双歧杆菌的增殖。然而,当His和Pro分别与0.5%FOS一起添加时,观察到比单独用FOS更显著的双歧杆菌的增殖。
因此,在本发明中,通过组合氨基酸和寡糖,在双歧杆菌的增殖方面观察到超过加和效应的协同效应。
[试验例 2] 向人粪便悬浮液中添加氨基酸和低聚半乳糖的试验
制备表2中所示的实施例和比较例的PBS溶液,并作为粪便培养用的培养基。根据与试验例1-1中的方法类似的方法,进行粪便培养和双歧杆菌的检测。使用和光纯药工业公司制造的低聚半乳糖(GOS)(#076-05945)。
[表2]
。
使用通过定量PCR获得的结果,计算将对照设为1时的相对量,并将其结果用Z-score标准化。
结果示于图 2中。数据以Z-score的平均值±标准误差表示(n=3)。其结果,当以任何浓度单独添加氨基酸时,未观察到双歧杆菌的增殖。然而,当Glu和Lys分别与0.5%GOS一起添加时,观察到比单独用GOS更显著的双歧杆菌的增殖。此外,当Glu和Lys混合并与0.5%GOS一起添加时,类似地观察到比单独用GOS更显著的双歧杆菌的增殖。
因此,在本发明中,通过组合氨基酸和寡糖(与其种类无关),在双歧杆菌的增殖方面观察到超过加和效应的协同效应。
[试验例 3] 向猪施用肠溶性Lys和FOS的试验
从ZEN-NOH(日本全国农业协同组合联合会)购买2至3个月大的雄性猪(HI-COOP SPF猪LWD)6头,分成2个试验组,每组包含3头猪,使得平均体重均匀,并以3头猪/圈饲养4周。在每个试验组中,每天两次喂食400g/头的猪MIRAI CEX(ZEN-NOH)。在每个试验组中,采用表3中所示的用量和方法施用测试物质。将味之素株式会社制造的用于奶牛的赖氨酸制剂“AjiPro-L”(赖氨酸盐酸盐含量为40%或更高)用作肠溶性Lys,并且将明治Food Materia公司制造的低聚果糖 “Meioligo P颗粒”(FOS含量为95%或更高)用作FOS。从施用开始经过4周后,采集盲肠,并以与试验例1-1、1-2和2中相同的方法通过定量PCR检查盲肠内容物中的双歧杆菌。使用安捷伦(Agilent)公司制造的6470 Triple Quad LC/MS/MS系统和Imtakt公司制造的Intrada氨基酸柱测量盲肠内容物中的Lys浓度。
[表3]
。
通过定量PCR获得的结果,以将比较例24(安慰剂)设为1时的相对量表示。盲肠内双歧杆菌相对量的结果示于图3中(平均值±标准误差,n=3)。其结果,通过肠溶性Lys和FOS的组合,可以确认以平均值计比单独摄取FOS高约3倍的猪肠道内双歧杆菌的增殖效果。
此外,此时盲肠内Lys浓度的结果示于图4中(平均值±标准误差,n=3)。其结果,可以确认肠溶性Lys摄取组中盲肠内的Lys浓度增加。
因此,通过摄取肠溶性Lys而使下消化道中的Lys浓度增加,藉此观察到与低聚果糖的协同效应。
本申请基于在日本提交的专利申请No.2017-063145,其内容全部包含在本说明书中。
<110> 味之素株式会社
<120> 用于改善肠道内环境的食品
<130> 092706
<150> JP 2017-063145
<151> 2017-03-28
<160> 2
<170> PatentIn version 3.5
<210> 1
<211> 17
<212> DNA
<213> 人工序列
<220>
<223> 引物
<400> 1
ctcctggaaa cgggtgg 17
<210> 2
<211> 22
<212> DNA
<213> 人工序列
<220>
<223> 引物
<400> 2
ggtgttcttc ccgatatcta ca 22
Claims (8)
1.一种用于改善肠道内环境的食品,其特征在于,该食品是将下述的(1)和(2)组合而成:
(1)含有氨基酸或其盐的肠溶性组合物、
(2)难消化性多糖类或含有难消化性多糖类的组合物。
2.根据权利要求1所述的食品,其中,难消化性多糖类或含有难消化性多糖类的组合物为寡糖或含有寡糖的组合物。
3.根据权利要求1或2所述的食品,其中,氨基酸为选自丙氨酸、谷氨酰胺、谷氨酸、异亮氨酸、组氨酸、赖氨酸、脯氨酸及缬氨酸中的一种或两种以上的组合。
4.根据权利要求1或2所述的食品,其中,氨基酸为谷氨酸、赖氨酸、或者谷氨酸与赖氨酸的组合。
5.根据权利要求1至4中任一项所述的食品,其中,肠溶性组合物为颗粒剂、粒化物、片剂、硬胶囊或软胶囊。
6.一种食品,其特征在于,该食品用于改善肠道内环境,并且该食品是将下述的(1)和(2)组合而成:
(1)含有氨基酸或其盐的肠溶性组合物、
(2)难消化性多糖类或含有难消化性多糖类的组合物。
7.一种改善人肠道内环境的方法,其特征在于,由人摄取有效量的将下述的(1)和(2)组合而成的食品:
(1)含有氨基酸或其盐的肠溶性组合物、
(2)难消化性多糖类或含有难消化性多糖类的组合物。
8.(1)含有氨基酸或其盐的肠溶性组合物及(2)难消化性多糖类或含有难消化性多糖类的组合物在制造用于改善肠道内环境的食品中的用途。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017-063145 | 2017-03-28 | ||
JP2017063145 | 2017-03-28 | ||
PCT/JP2018/013052 WO2018181619A1 (ja) | 2017-03-28 | 2018-03-28 | 腸内環境改善用食品 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110402088A true CN110402088A (zh) | 2019-11-01 |
Family
ID=63676339
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880019869.7A Pending CN110402088A (zh) | 2017-03-28 | 2018-03-28 | 用于改善肠道内环境的食品 |
Country Status (5)
Country | Link |
---|---|
US (2) | US11426347B2 (zh) |
EP (2) | EP3603421A4 (zh) |
JP (1) | JP7031662B2 (zh) |
CN (1) | CN110402088A (zh) |
WO (2) | WO2018181619A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018181619A1 (ja) | 2017-03-28 | 2018-10-04 | 味の素株式会社 | 腸内環境改善用食品 |
WO2023145624A1 (ja) * | 2022-01-27 | 2023-08-03 | 京セラ株式会社 | 腸内情報推定システム |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002226369A (ja) * | 2001-01-30 | 2002-08-14 | Otsuka Pharmaceut Co Ltd | グルタミン含有経口組成物 |
WO2010098822A1 (en) * | 2009-02-24 | 2010-09-02 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
CN103458709A (zh) * | 2011-01-21 | 2013-12-18 | 凡赛尔医药股份有限公司 | 微囊化益生菌物质及其制造方法 |
JP2014091720A (ja) * | 2012-11-05 | 2014-05-19 | Kyowa Hakko Bio Co Ltd | 血流促進剤 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3382871B2 (ja) * | 1999-02-26 | 2003-03-04 | 株式会社東洋新薬 | 健康食品 |
CA2455012C (en) * | 2001-07-27 | 2007-10-09 | N.V. Nutricia | Enteral compositions for the prevention and/or treatment of sepsis |
US7754677B2 (en) * | 2003-12-05 | 2010-07-13 | Hill's Pet Nutrition, Inc. | Composition and method for reducing diarrhea in a mammal |
CA2608670C (en) * | 2005-05-20 | 2019-03-05 | Hill's Pet Nutrition, Inc. | Methods for promoting health or wellness in adult animals |
HUP0500582A1 (hu) * | 2005-06-13 | 2007-08-28 | Csaba Jozsef Dr Jaszberenyi | Szinergetikus élettani hatású élelmiszerek, élelmiszer-adalékok és táplálék-kiegészítõk vagy takarmányadalékok |
US7595079B2 (en) * | 2005-07-08 | 2009-09-29 | Bomac Vets Plus, Inc. | Nutritional conjunctive support therapy for recovery in animals following stress or illness |
US8524304B2 (en) | 2005-11-23 | 2013-09-03 | The Coca-Cola Company | High-potency sweetener composition with probiotics/prebiotics and compositions sweetened therewith |
WO2009054360A1 (ja) * | 2007-10-22 | 2009-04-30 | Kyowa Hakko Bio Co., Ltd. | 内臓脂肪特異的低減剤 |
JP5852558B2 (ja) * | 2010-03-26 | 2016-02-03 | 株式会社明治 | 腸管免疫の抑制剤のスクリーニング方法 |
EP2842561A4 (en) | 2012-04-26 | 2016-07-27 | J Oil Mills Inc | MEANS FOR OPTIMIZING THE ENTERAL ENVIRONMENT |
JP6212036B2 (ja) * | 2012-05-11 | 2017-10-11 | 協和発酵バイオ株式会社 | 肌質改善剤 |
US9765151B2 (en) | 2013-03-11 | 2017-09-19 | Cured Inc. | Method for producing monoclonal IgA antibody |
CN105120847B (zh) * | 2013-03-14 | 2018-12-28 | 塞拉拜姆有限责任公司 | 益生生物和/或治疗剂的靶向胃肠道递送 |
JPWO2015137387A1 (ja) * | 2014-03-11 | 2017-04-06 | 協和発酵バイオ株式会社 | 筋肉増強剤 |
CN104286542A (zh) * | 2014-10-20 | 2015-01-21 | 山东绿都安特动物药业有限公司 | 猪用抗应激促生长改善新陈代谢的调节剂及其制备方法 |
CA2983016A1 (en) | 2015-04-23 | 2016-10-27 | Kaleido Biosciences, Inc. | Microbiome regulators and related uses thereof |
JP6566812B2 (ja) | 2015-09-25 | 2019-08-28 | 三菱電機株式会社 | 炭化珪素半導体装置及びその製造方法 |
WO2018181619A1 (ja) | 2017-03-28 | 2018-10-04 | 味の素株式会社 | 腸内環境改善用食品 |
-
2018
- 2018-03-28 WO PCT/JP2018/013052 patent/WO2018181619A1/ja unknown
- 2018-03-28 CN CN201880019869.7A patent/CN110402088A/zh active Pending
- 2018-03-28 EP EP18777450.0A patent/EP3603421A4/en active Pending
- 2018-03-28 JP JP2019510072A patent/JP7031662B2/ja active Active
- 2018-03-28 WO PCT/JP2018/013054 patent/WO2018181621A1/ja unknown
- 2018-03-28 EP EP18777193.6A patent/EP3603420A4/en active Pending
-
2019
- 2019-09-23 US US16/579,135 patent/US11426347B2/en active Active
- 2019-09-23 US US16/579,191 patent/US11376215B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002226369A (ja) * | 2001-01-30 | 2002-08-14 | Otsuka Pharmaceut Co Ltd | グルタミン含有経口組成物 |
WO2010098822A1 (en) * | 2009-02-24 | 2010-09-02 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
CN103458709A (zh) * | 2011-01-21 | 2013-12-18 | 凡赛尔医药股份有限公司 | 微囊化益生菌物质及其制造方法 |
JP2014091720A (ja) * | 2012-11-05 | 2014-05-19 | Kyowa Hakko Bio Co Ltd | 血流促進剤 |
Also Published As
Publication number | Publication date |
---|---|
JP7031662B2 (ja) | 2022-03-08 |
WO2018181621A1 (ja) | 2018-10-04 |
US20200009167A1 (en) | 2020-01-09 |
EP3603421A1 (en) | 2020-02-05 |
US20200009046A1 (en) | 2020-01-09 |
WO2018181619A1 (ja) | 2018-10-04 |
EP3603420A1 (en) | 2020-02-05 |
EP3603420A4 (en) | 2021-04-14 |
US11426347B2 (en) | 2022-08-30 |
JPWO2018181619A1 (ja) | 2020-02-06 |
EP3603421A4 (en) | 2021-02-17 |
US11376215B2 (en) | 2022-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112020017090A2 (pt) | Imunoterapias relacionadas com microbioma | |
CN110075130A (zh) | 益生生物和/或治疗剂的靶向胃肠道递送 | |
JP4596304B2 (ja) | 成長ホルモン分泌促進組成物 | |
JP5592640B2 (ja) | 乳酸菌発酵ローヤルゼリーを含有する抗ストレス剤、その製造方法、視床下部−下垂体−副腎皮質系の活動抑制剤、及び交感神経−副腎髄質系の活動抑制剤 | |
US20200316023A1 (en) | Method Of Producing Bacterially Derived Indole-3-Propionic Acid And Compositions Comprising Same | |
CN110402088A (zh) | 用于改善肠道内环境的食品 | |
TW201716079A (zh) | Glp-2分泌促進用組成物 | |
CN103142633B (zh) | 包含八种氨基酸和十一种维生素的复方氨基酸胶囊 | |
US9289461B2 (en) | Reducing the risk of autoimmune disease | |
WO2021097288A1 (en) | Compositions and methods for treating neurodegenerative diseases | |
TWI343813B (zh) | ||
CN108402473B (zh) | 一种具有改善记忆功能的用于口服的脑多肽组合物 | |
US8343925B2 (en) | Composition for improving brain function and method for improving brain function | |
US20200276321A1 (en) | Composition and method for a prebiotic delivery system targeted to probiotic bacteria | |
Chomová et al. | Development and evaluation of a fish feed mixture containing the probiotic Lactiplantibacillus plantarum prepared using an innovative pellet coating method | |
TW201442716A (zh) | 含有雙叉桿菌的安定組成物 | |
US11273169B2 (en) | Food for improving intestinal environment | |
CN104666264B (zh) | 一种盐酸氨基葡萄糖咀嚼片及其制备方法 | |
AU2011236979B2 (en) | Composition for amelioration of hypoalbuminemia | |
WO2020203667A1 (ja) | 有用微生物の菌体の保護方法 | |
CN112450448A (zh) | 一种含有分离乳清蛋白的乳铁蛋白组合物及其制备工艺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |